Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Purchased by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 34.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,956 shares of the medical equipment provider's stock after acquiring an additional 3,554 shares during the quarter. Fort Washington Investment Advisors Inc. OH's holdings in Zimmer Biomet were worth $1,580,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Stonebridge Financial Group LLC acquired a new position in Zimmer Biomet in the 4th quarter valued at about $25,000. Menard Financial Group LLC acquired a new position in shares of Zimmer Biomet during the fourth quarter worth about $30,000. Accredited Wealth Management LLC acquired a new position in shares of Zimmer Biomet during the fourth quarter worth about $36,000. OFI Invest Asset Management acquired a new position in shares of Zimmer Biomet during the fourth quarter worth about $40,000. Finally, Dunhill Financial LLC grew its position in shares of Zimmer Biomet by 86.6% during the fourth quarter. Dunhill Financial LLC now owns 444 shares of the medical equipment provider's stock worth $47,000 after buying an additional 206 shares in the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

Zimmer Biomet stock traded down $2.03 during trading hours on Friday, reaching $91.23. 1,370,283 shares of the stock were exchanged, compared to its average volume of 1,791,171. The stock has a market cap of $18.05 billion, a P/E ratio of 20.50, a P/E/G ratio of 1.95 and a beta of 0.72. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.22 and a 52-week high of $116.71. The firm's 50 day moving average is $96.48 and its 200 day moving average is $103.50.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $1.91 billion during the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. Zimmer Biomet's quarterly revenue was up 1.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.94 EPS. Analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 26th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.05%. Zimmer Biomet's dividend payout ratio is presently 21.24%.

Analyst Ratings Changes

A number of brokerages have recently commented on ZBH. JPMorgan Chase & Co. lowered their price objective on Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating for the company in a research report on Tuesday, May 6th. The Goldman Sachs Group lowered their price objective on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating for the company in a research report on Tuesday, May 6th. Canaccord Genuity Group lowered their price target on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating for the company in a report on Monday, May 12th. Truist Financial set a $101.00 price objective on shares of Zimmer Biomet in a report on Tuesday, May 6th. Finally, Royal Bank of Canada lowered their target price on shares of Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $111.53.

Insider Activity

In other news, insider Sang Yi sold 1,000 shares of the stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total value of $95,000.00. Following the completion of the transaction, the insider now owns 20,424 shares in the company, valued at $1,940,280. This trade represents a 4.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.39% of the company's stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.